ADC Therapeutics(ADCT)
$1.60+0.09 (+5.96%)
ADCT
ADC Therapeutics financials statements
$1.60
At close:+0.09 (+5.96%)
Want to see ADCT full AI Analyst Report?
ADC Therapeutics (ADCT) Ratios
441 Followers
ADC Therapeutics Ratios
ADCT's free cash flow for Q3 2026 was $-27.88M. For the 2026 fiscal year, ADCT's free cash flow was decreased by $-139.00 and operating cash flow was $-27.88M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.37 | 3.82 | 4.97 | 5.31 | 7.10 |
| Quick Ratio | 4.31 | 3.59 | 4.73 | 5.16 | 6.95 |
| Cash Ratio | 3.72 | 3.12 | 4.12 | 3.98 | 6.31 |
| Solvency Ratio | -0.28 | -0.29 | -0.47 | -0.38 | -0.50 |
| Operating Cash Flow Ratio | -2.01 | -1.54 | -1.75 | -1.69 | -3.16 |
| Short-Term Operating Cash Flow Coverage | -47.06 | 0.00 | 0.00 | -11.09 | -35.49 |
| Net Current Asset Value | $ -202.65M | $ -217.23M | $ -166.74M | $ 23.57M | $ 73.30M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 1.36 | 0.38 | 0.35 | 0.26 | 0.23 |
| Debt-to-Equity Ratio | -2.36 | -0.61 | -0.84 | 1.63 | 0.84 |
| Debt-to-Capital Ratio | 1.73 | -1.54 | -5.21 | 0.62 | 0.46 |
| Long-Term Debt-to-Capital Ratio | 1.74 | -1.28 | -3.17 | 0.58 | 0.43 |
| Financial Leverage Ratio | -1.74 | -1.59 | -2.39 | 6.18 | 3.72 |
| Debt Service Coverage Ratio | -1.63 | -2.05 | -3.99 | -2.19 | -8.39 |
| Interest Coverage Ratio | -2.10 | -2.60 | -3.58 | -3.36 | -14.27 |
| Debt to Market Cap | 0.98 | 0.59 | 0.83 | 0.41 | 0.08 |
| Interest Debt Per Share | 3.86 | 1.78 | 2.09 | 2.13 | 2.06 |
| Net Debt to EBITDA | -1.99 | 1.25 | 1.06 | 1.83 | 1.42 |
| Profitability Margins | |||||
| Gross Profit Margin | 90.57% | 91.60% | 96.36% | 98.43% | 95.89% |
| EBIT Margin | -112.03% | -149.53% | -214.34% | -52.44% | -687.46% |
| EBITDA Margin | -109.73% | -144.91% | -209.65% | -51.31% | -679.70% |
| Operating Profit Margin | -133.21% | -184.44% | -238.63% | -58.76% | -771.65% |
| Pretax Profit Margin | -175.50% | -222.60% | -288.89% | -74.75% | -741.53% |
| Net Profit Margin | -175.31% | -222.83% | -345.11% | -74.86% | -678.20% |
| Continuous Operations Profit Margin | -175.31% | -222.83% | -345.11% | -74.86% | -678.20% |
| Net Income Per EBT | 99.89% | 100.11% | 119.46% | 100.14% | 91.46% |
| EBT Per EBIT | 131.74% | 120.69% | 121.06% | 127.21% | 96.10% |
| Return on Assets (ROA) | -44.14% | -49.02% | -67.66% | -32.01% | -37.22% |
| Return on Equity (ROE) | 76.75% | 77.89% | 161.93% | -197.77% | -138.50% |
| Return on Capital Employed (ROCE) | -42.84% | -54.10% | -57.81% | -30.16% | -48.11% |
| Return on Invested Capital (ROIC) | -42.29% | -53.79% | -57.52% | -29.19% | -43.39% |
| Return on Tangible Assets | -44.14% | -49.02% | -67.66% | -32.98% | -38.06% |
| Earnings Yield | -31.80% | -81.64% | -176.98% | -52.36% | -14.84% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.79 | 3.49 | 2.76 | 2.88 | 1.05 |
| Payables Turnover | 0.84 | 0.33 | 0.16 | 0.27 | 0.12 |
| Inventory Turnover | 1.83 | 0.32 | 0.16 | 0.27 | 0.13 |
| Fixed Asset Turnover | 62.73 | 5.27 | 4.31 | 20.46 | 3.02 |
| Asset Turnover | 0.25 | 0.22 | 0.20 | 0.43 | 0.05 |
| Working Capital Turnover Ratio | 0.35 | 0.29 | 0.22 | 0.52 | 0.08 |
| Cash Conversion Cycle | -106.76 | 126.65 | 219.89 | 96.15 | 95.14 |
| Days of Sales Outstanding | 130.63 | 104.68 | 132.14 | 126.89 | 346.16 |
| Days of Inventory Outstanding | 199.00 | 1128.13 | 2334.76 | 1334.94 | 2914.24 |
| Days of Payables Outstanding | 436.39 | 1106.17 | 2247.01 | 1365.68 | 3165.25 |
| Operating Cycle | 329.63 | 1232.81 | 2466.90 | 1461.83 | 3260.39 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.11 | -1.27 | -1.45 | -1.77 | -3.04 |
| Free Cash Flow Per Share | -1.11 | -1.28 | -1.49 | -1.78 | -3.12 |
| Dividend Paid and CapEx Coverage Ratio | -534.75 | -142.83 | -36.90 | -201.33 | -36.60 |
| Capital Expenditure Coverage Ratio | -534.75 | -142.83 | -36.90 | -201.33 | -36.60 |
| Operating Cash Flow Coverage Ratio | -0.32 | -1.01 | -0.95 | -1.07 | -1.67 |
| Operating Cash Flow to Sales Ratio | -1.74 | -1.75 | -1.71 | -0.66 | -6.88 |
| Free Cash Flow Yield | -31.53% | -64.50% | -89.87% | -46.32% | -15.46% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.15 | -1.23 | -0.57 | -1.91 | -6.74 |
| Price-to-Sales (P/S) Ratio | 5.51 | 2.73 | 1.95 | 1.43 | 45.71 |
| Price-to-Book (P/B) Ratio | -2.41 | -0.95 | -0.91 | 3.78 | 9.33 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.17 | -1.55 | -1.11 | -2.16 | -6.47 |
| Price-to-Operating Cash Flow Ratio | -3.18 | -1.56 | -1.14 | -2.17 | -6.64 |
| Price-to-Earnings Growth (PEG) Ratio | 0.10 | 0.03 | -0.01 | 0.06 | 0.33 |
| Enterprise Value Multiple | -7.01 | -0.64 | 0.13 | -0.96 | -5.31 |
| Enterprise Value | 626.22M | 65.48M | -18.58M | 103.52M | 1.22B |
| EV to EBITDA | -7.01 | -0.64 | 0.13 | -0.96 | -5.31 |
| EV to Sales | 7.70 | 0.92 | -0.27 | 0.49 | 36.07 |
| EV to Free Cash Flow | -4.43 | -0.53 | 0.15 | -0.74 | -5.10 |
| EV to Operating Cash Flow | -4.44 | -0.53 | 0.16 | -0.75 | -5.24 |
| Tangible Book Value Per Share | -1.46 | -2.09 | -1.81 | 0.83 | 1.99 |
| Shareholders’ Equity Per Share | -1.46 | -2.09 | -1.81 | 1.02 | 2.16 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | -0.00 | -0.19 | -0.00 | 0.09 |
| Revenue Per Share | 0.64 | 0.73 | 0.85 | 2.69 | 0.44 |
| Net Income Per Share | -1.12 | -1.62 | -2.94 | -2.01 | -3.00 |
| Tax Burden | 1.00 | 1.00 | 1.19 | 1.00 | 0.91 |
| Interest Burden | 1.57 | 1.49 | 1.35 | 1.43 | 1.08 |
| Research & Development to Revenue | 1.28 | 1.55 | 1.83 | 0.89 | 4.66 |
| SG&A to Revenue | -0.08 | 1.21 | 1.05 | 0.51 | 2.11 |
| Stock-Based Compensation to Revenue | 0.08 | 0.09 | 0.19 | 0.24 | 1.78 |
| Income Quality | 0.99 | 0.78 | 0.49 | 0.88 | 1.01 |
Currency in USD
